Literature DB >> 10197371

The treatment of tuberculosis in HIV-infected persons.

A L Pozniak, R Miller, L P Ormerod.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10197371     DOI： 10.1097/00002030-199903110-00001

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  16 in total

1.  Extrapulmonary tuberculosis masking disseminated histoplasmosis in AIDS.

Authors:  L Greene; B Peters; S B Lucas; A L Pozniak
Journal:  Sex Transm Infect       Date:  2000-02       Impact factor: 3.519

2.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

3.  Pyrexia of undetermined origin in the era of HAART.

Authors:  W Whitely; A Tariq; B Peters; G Kocjan; R F Miller
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

Review 4.  Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?

Authors:  R F Miller
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 5.  Tuberculosis and HIV co-infection: a practical therapeutic approach.

Authors:  Ronan A M Breen; Leonie Swaden; Jayne Ballinger; Marc C I Lipman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Inferior vena cava filters for HIV infected patients with pulmonary embolism and contraindications to anticoagulation.

Authors:  M Shahmanesh; J Brooks; P J Shaw; R F Miller
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

7.  Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.

Authors:  E Ribera; L Pou; A Fernandez-Sola; F Campos; R M Lopez; I Ocaña; I Ruiz; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

Authors:  Luis F López-Cortés; Rosa Ruiz-Valderas; Pompeyo Viciana; Aristides Alarcón-González; Jesús Gómez-Mateos; Eva León-Jimenez; Maria Sarasanacenta; Yolanda López-Pua; Jerónimo Pachón
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.

Authors:  C J L la Porte; E P H Colbers; R Bertz; D S Voncken; K Wikstrom; M J Boeree; P P Koopmans; Y A Hekster; D M Burger
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil.

Authors:  A P G dos Santos; A G Pacheco; A Staviack; J E Golub; R E Chaisson; V C Rolla; A L Kritski; S R L Passos; F C de Queiroz Mello
Journal:  Int J Tuberc Lung Dis       Date:  2013-02       Impact factor: 2.373
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.